SCC148
MB49 Mouse Bladder Carcinoma Cell Line
Mouse
Synonym(s):
MB-49
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
41106514
eCl@ss:
32011203
NACRES:
NA.81
Recommended Products
product name
MB49 Mouse Bladder Carcinoma Cell Line, MB49 mouse urothelial carcinoma cell line is widely used as an in vitro and in vivo model of bladder cancer.
biological source
mouse
Quality Level
technique(s)
cell culture | mammalian: suitable
shipped in
ambient
General description
MB49 cells are derived from C57BL/Icrf-a’ mouse bladder epithelial cells that were transformed by a single 24-hour treatment with the chemical carcinogen 7, 12-dimethylbenz[a]anthracene (DMBA) on the second day of a long term primary culture . Transformed cells transplanted into syngeneic mice were shown to generate carcinomas . While of male origin, karyotype analyses indicate the loss of the Y chromosome in 100% of the cells analyzed . This abnormality is a frequent early event in human bladder cancer. A recent study indicates that MB49 cells recapitulate key features of sex differences in bladder tumor growth . MB49 implantation in mice resulted in significantly larger tumors in males than females. In the presence of dihydrotestosterone, MB49 cells exhibited enhanced proliferation in a dose-dependent manner. In contrast, MB49 cells were unresponsive to the pregnancy hormone, human chorionic gonadotrophin (hCG) . MB49 cells exhibit low to no expression of MHC-Class I and II molecules . However, upon exposure to IFN-, the expressions of MHC Class I and II are significantly upregulated .
Quality
• Each vial contains ≥ 1X106 viable cells.
• Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are negative for mycoplasma contamination
• Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are negative for mycoplasma contamination
Other Notes
This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the "Academic Use Agreement" as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
E C Lattime et al.
Cancer research, 52(15), 4286-4290 (1992-08-01)
Intravesical administration of Bacillus Calmette-Guérin (BCG) is the most effective therapy for superficial transitional cell carcinoma of the bladder although its mechanism of action is not known. To determine if bladder tumors are capable of antigen presentation and thus might
Zheng Zhu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(21), 4820-4831 (2022-08-04)
Immune checkpoint inhibitors (ICI) in general have shown poor efficacy in bladder cancer. The purpose of this project was to determine whether photodynamic therapy (PDT) with bladder cancer-specific porphyrin-based PLZ4-nanoparticles (PNP) potentiated ICI. SV40 T/Ras double-transgenic mice bearing spontaneous bladder
Mathieu Rouanne et al.
The Journal of clinical investigation, 132(12) (2022-05-04)
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human
Vanessa Bellat et al.
Cancer research, 82(7), 1409-1422 (2022-01-19)
The standard treatment of nonmuscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intravesical therapy (IT), which comprises a direct instillation of a solution of Bacillus Calmette-Guérin vaccine or chemotherapy into the bladder. However, the recurrence
Guangchuan Wang et al.
Cancer discovery, 10(12), 1912-1933 (2020-09-06)
Immune checkpoint blockade (ICB) has shown remarkable clinical efficacy in several cancer types. However, only a fraction of patients will respond to ICB. Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMM) in ICB settings, and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service